Literature DB >> 2966024

High affinity aldosterone binding sites (type I receptors) in rat heart.

P Pearce1, J W Funder.   

Abstract

1. The use of the receptor stabilizing agent sodium molybdate, and of RU26988 to exclude [3H]-aldosterone binding from Type II glucocorticoid receptors, has enabled the characterization of high affinity Type I aldosterone binding sites in rat atrial and ventricular cytosols. 2. In adult male and female rats the affinity of binding (Kd 4 degrees C) is approximately 1-2 nmol/l for both atria and ventricles; specificity of binding is similar to that for Type I sites in classical aldosterone target tissues (aldosterone = corticosterone much greater than dexamethasone). 3. Levels of atrial Type I sites are higher than the corresponding levels in ventricle in both males and females, whereas for Type II (classical glucocorticoid) receptors the reverse is the case; levels of both Type I and Type II sites fall over the age range examined (40 days-6 months). 4. The physiological function(s) of cardiac Type I sites, and their in vivo mineralocorticoid or glucocorticoid selectivity, remain to be explored.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2966024     DOI: 10.1111/j.1440-1681.1987.tb02422.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  15 in total

Review 1.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

3.  Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signaling.

Authors:  Cherish Chong; Anis Hamid; Tham Yao; Amanda E Garza; Luminita H Pojoga; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  J Endocrinol       Date:  2017-01-17       Impact factor: 4.286

Review 4.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 5.  The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.

Authors:  A Hameedi; H L Chadow
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

6.  Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action.

Authors:  M C Zennaro; D Le Menuet; S Viengchareun; F Walker; D Ricquier; M Lombès
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

Review 7.  Mineralocorticoid receptors: distribution and activation.

Authors:  John W Funder
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

8.  Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.

Authors:  Walmor C De Mello; Yamil Gerena
Journal:  Regul Pept       Date:  2008-06-08

Review 9.  Aldosterone and aldosterone antagonism in systemic hypertension.

Authors:  William H Frishman; Charles T Stier
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 10.  Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart.

Authors:  Morag J Young; Monica Kanki; Peter J Fuller; Jun Yang
Journal:  J Hum Hypertens       Date:  2020-07-30       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.